This is consistent with the previous study, which showed that the superior benefits of EGFR-TKIs plus brain RT might be influenced by factors such as BM-related symptoms and mutation type, compared with EGFR-TKIs alone in the management of EGFR-mutated NSCLC patients with BMs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.